Biogen Pharmachem Industries Ltd (531752)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Biogen Pharmachem's revenue was ₹0.4 Cr, and net profit ₹0.2 Cr (-83.5% year on year); the operating margin was 49.9%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹0.4 | — | -23.6% |
| Operating profit | ₹0.2 | from loss | from loss |
| Net profit | ₹0.2 | -83.5% | from loss |
| EPS (₹) | 0.00 | -100.0% | — |
| Operating margin | 49.9% | — | — |
📢 Recent Corporate Announcements
Biogen Pharmachem Industries Ltd has issued the notice for its 31st Annual General Meeting scheduled for September 29, 2026, via video conferencing. Key ordinary business items include the adoption of FY26 audited financial statements, the reappointment of retiring director Mr. Kelash Bunkar, and the reappointment of statutory auditor M/s. Goenka Mehta & Associates until the 2031 AGM. The register of members and share transfer books will remain closed from September 22 to September 29, 2026.
- 31st AGM scheduled for Tuesday, 29th September 2026 at 4:00 PM IST via VC/OAVM
- Remote e-voting window opens on 26th September 2026 (09:00 AM) and closes on 28th September 2026 (05:00 PM)
- Cut-off date for voting eligibility set as Tuesday, 22nd September 2026
- Proposed reappointment of statutory auditors M/s Goenka Mehta & Associates (FRN: 129445W) from conclusion of this AGM until AGM in 2031
Biogen Pharmachem Industries has submitted its quarterly statement of deviation or variation for the period ending June 30, 2026. The company confirmed that it has no unutilized funds remaining from any past public, rights, or preferential issues, or Qualified Institutional Placements (QIP). As all previously raised capital has been fully deployed, the company reported no deviations from the objects stated in its offer documents. This is a routine compliance filing required under SEBI Regulation 32(1).
- Zero unutilized funds reported as of June 30, 2026
- No deviation or variation in the use of proceeds from past capital raises
- Filing covers all past public, rights, and preferential issues
- Compliance maintained with SEBI Circular dated 24th December, 2019
Biogen Pharmachem reported a net profit of ₹0.22 crore for the quarter ended June 30, 2026, marking a recovery from a loss of ₹0.36 crore in the previous quarter (Q4 FY26). However, the company's revenue from operations witnessed a sharp 71.2% year-on-year decline, falling to ₹0.44 crore from ₹1.54 crore in Q1 FY26. The return to profitability was primarily driven by a significant reduction in total expenses, which dropped to ₹0.22 crore from ₹0.94 crore in the preceding quarter. Despite the profit, the absolute scale of operations remains extremely small for a company with a ₹28 crore market cap.
- Revenue from operations fell 71.2% YoY to ₹44.34 lacs (₹0.44 cr) from ₹154.28 lacs.
- Net profit stood at ₹22.14 lacs (₹0.22 cr) compared to a loss of ₹35.88 lacs in the previous quarter.
- Total expenses were reduced by 76.3% sequentially to ₹22.20 lacs from ₹93.70 lacs.
- Paid-up equity share capital increased to ₹105.30 cr from ₹90.26 cr in the year-ago period.
- Earnings Per Share (EPS) remained negligible at ₹0.00 for the quarter.
Biogen Pharmachem Industries reported a net profit of ₹22.14 lakhs for the quarter ended June 30, 2026, marking a recovery from a net loss of ₹35.88 lakhs in the preceding March quarter. However, revenue from operations declined 23% quarter-on-quarter to ₹44.34 lakhs and fell sharply by 71% compared to ₹154.28 lakhs in the year-ago period. The company's paid-up equity share capital increased to ₹105.30 Cr from ₹90.26 Cr. Despite the revenue drop, profitability was achieved through a significant reduction in total expenses, which fell to ₹22.20 lakhs from ₹93.70 lakhs in the previous quarter.
- Net profit of ₹22.14 lakhs in Q1 FY27 vs a loss of ₹35.88 lakhs in Q4 FY26
- Revenue from operations fell 71.2% year-on-year to ₹44.34 lakhs from ₹154.28 lakhs
- Total expenses reduced by 76% quarter-on-quarter to ₹22.20 lakhs
- Paid-up equity share capital increased by ₹15.04 Cr to ₹105.30 Cr during the quarter
- Earnings Per Share (EPS) remained flat at ₹0.00 for the quarter
Biogen Pharmachem Industries Ltd has scheduled a board meeting for August 5, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. This is a routine regulatory filing for the micro-cap company, which has a market capitalization of Rs 30 Cr. The company reported a net loss of Rs 0.36 Cr in the previous quarter (March 2026) on revenue of Rs 0.58 Cr. Investors will be looking for signs of recovery given the TTM revenue is only Rs 1 Cr.
- Board meeting scheduled for August 5, 2026, to approve Q1 FY27 results
- Company reported a TTM revenue of only Rs 1 Cr against a net worth of Rs 99 Cr
- Operating profit margin remains highly volatile at -43.7% TTM
- Stock has seen a significant price decline of 59.9% over the last 12 months
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
